GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » Institutional Ownership

Alphamab Oncology (STU:3NK) Institutional Ownership : 5.03% (As of Apr. 14, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alphamab Oncology's institutional ownership is 5.03%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alphamab Oncology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alphamab Oncology's Float Percentage Of Total Shares Outstanding is 0.00%.


Alphamab Oncology Institutional Ownership Historical Data

The historical data trend for Alphamab Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Institutional Ownership Chart

Alphamab Oncology Historical Data

The historical data trend for Alphamab Oncology can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 6.08 6.05 5.01 4.85 4.85 4.89 4.87 4.87 4.86 5.03

Alphamab Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Alphamab Oncology Business Description

Traded in Other Exchanges
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Alphamab Oncology Headlines

No Headlines